drugset
drugset / Trial / NCT04657315

Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

NCT04657315 ↗

Phase 1/2 Completed 10 enrolled CHA University Ajou University School of Medicine · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I trial evaluating the maximum tolerated dose, safety and efficiency of Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD), injected into the resection cavity of patients with recurrent glioblastoma.

Timeline

Start
2020-06-24
Primary completion
2022-12-22
Completion
2022-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject MSC11FCD Cell therapy 1e+07 cells Other
Subject MSC11FCD Cell therapy 3e+07 cells Other
Background 5 flucytosine Unknown 150 mg/kg Oral

Indications

gliosarcoma